Form D · Biotechnology
Cardax Pharmaceuticals Inc
Honolulu, HI · CIK 0001408223
Offering snapshot reported Sep 28, 2010 · SEC filing
- Reported sold
- $550K Offering amount: $2M
- Investors reported
- 4 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 23, 2010 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 28, 2010 | Initial | $550,000 | No comparison | 4 | SEC filing |
| Dec 23, 2008 | Initial | $600,000 | No comparison | Not reported | SEC filing |
| Jul 26, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Debt, Option to acquire
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-148265
Source: Form D, filed Sep 28, 2010. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Thomas H. Goodin | Executive |
| Frank Herringer | Director |
| Nicholas Mitsakos | Director |
| Fredric J. Pashkow | Director, Executive |
| Frederic J. Pashkow | Director, Executive |
| David G. Watumull | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
2800 Woodlawn Drive Suite 129
Honolulu, HI, 96822
Honolulu, HI, 96822